Recurrent Childhood Acute Lymphoblastic Leukemia Completed Phase 1 / 2 Trials for DB00619 (Imatinib)

IndicationStatusPhase
DBCOND0028597 (Recurrent Childhood Acute Lymphoblastic Leukemia)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00702403Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaTreatment